On April 20, 2021 EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, reported that it has been selected as the Norwegian flagship company at the Nordic Life Science ("NLS") days conference with CEO, Dr Rafiq Hasan, participating in the opening plenary (Press release, Exact Therapeutics, APR 20, 2021, View Source [SID1234578288]). NLS Days is the largest Nordic partnering conference dedicated to the life science industry and is taking place April 20-23.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is a privilege to be selected as the flagship company from Norway at the NLS Days 2021 meeting alongside other great Nordic companies",
said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.
"NLS Days 2021 is a great opportunity to learn about the strong innovation emerging from the Nordic region, as well as to share
experiences and best practices. The conference comes at an exciting time for the Company with our ongoing Phase I ACTIVATE study, continued expansion in both Norway and the UK with key appointments, the opening of a new research facility and expanding technology collaboration with GE Healthcare.".
About ACT
ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
ACT is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
Initial focus of the company is oncology, however the ACT platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.